Guest guest Posted June 21, 2008 Report Share Posted June 21, 2008 Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia http://jco.ascopubs.org/cgi/content/short/JCO.2007.14.9260v1?rss=1 Blood counts and infections: https://www.pfizeroncology.com/patient-education/Blood_Counts_Infections.pdf Statins may reduce Graft Versus Host Disease: http://www.caring4cancer.com/go/Cancer/news?NewsItemId=42168 Blessings, Lottie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.